CLINICAL TRIALS ON EFFICACY OF ANTIVIRALS FOR TREATMENT

抗病毒药物治疗功效的临床试验

• 批准号: 3595310
• 负责人: RICHARD J WHITLEY
• 金额: $ 8.66万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-07-01 至 1991-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3595310
• 关键词: acyclovir; antiviral agents; combination chemotherapy; drug adverse effect; drug screening /evaluation; glia; host organism interaction; human subject; human therapy evaluation; neuritis; shingles; steroids

The objectives of the contract are to continue to test several antiviral therapies for effectiveness against localized herpes zoster in immune competent hosts. The annual incidence of herpes zoster is 3.4 cases per 1,000 individuals. In the normal host it is not life-threatening but 40% of patients over 50 years old suffer from a debilitating post-herpectic neuralgia. Therefore the development of an effective course of therapy which does not involve hospitalization is highly desirable. The three orally administered therapies that will be tested in this placebo-controlled double-blind trial are acyclovir, a steroid, and a combination of acyclovir with a steroid. It will be determined whether any of the therapies have a significant beneficial influence on the duration, healing and severity of lesions or the associated neuritis and neuralgia. In addition the toxicities of the several therapies will be assessed and the host's immune response will be analyzed.

合同的目标是继续测试几种抗病毒 免疫中针对局部疱疹带状疱疹的有效性的疗法 胜任的主人。 疱疹带状疱疹的年发病率为3.4例 1,000个人。 在普通主机中，它不是威胁生命的，而是40％ 50岁以上的患者患有令人衰弱的后毛病 神经痛。 因此，开发有效的治疗过程 不涉及住院是非常可取的。 将在此测试的三种口头管理疗法 安慰剂对照双盲试验是阿昔洛韦，类固醇和 Acyclovir与类固醇的组合。 将确定是否有 这些疗法对持续时间有重大的有益影响， 病变的愈合和严重程度或相关的神经炎和神经痛。 此外，将评估几种疗法的毒性，并 将分析宿主的免疫反应。